STOCK TITAN

CareDx (CDNA) CEO 10b5-1 sale: 10,156 shares at $21.05 average

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

CareDx, Inc. President and CEO John Walter Hanna Jr. reported a sale of company stock. On January 15, 2026, he sold 10,156 shares of CareDx common stock in an open-market transaction coded as a sale. The shares were sold at a weighted average price of $21.052 per share, with individual trade prices ranging from $21.00 to $21.18.

The sale was carried out under a pre-arranged Rule 10b5-1 trading plan that he adopted on December 13, 2024, which is designed to allow insiders to sell shares according to a preset schedule. After this transaction, he beneficially owned 616,885 shares of CareDx common stock directly.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hanna John Walter JR

(Last) (First) (Middle)
C/O CAREDX, INC.
8000 MARINA BOULEVARD, 4TH FLOOR

(Street)
BRISBANE CA 94005

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CareDx, Inc. [ CDNA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/15/2026 S(1) 10,156 D $21.052(2) 616,885 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2024.
2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.18 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ John Walter Hanna, Jr. 01/20/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CareDx (CDNA) report for its CEO?

CareDx reported that President and CEO John Walter Hanna Jr. sold 10,156 shares of common stock on January 15, 2026 in an open-market transaction.

At what price did the CareDx CEO sell shares in this Form 4 filing?

The weighted average sale price was $21.052 per share, with individual trades executed at prices between $21.00 and $21.18 per share.

How many CareDx (CDNA) shares does the CEO hold after this transaction?

Following the reported sale, the CEO beneficially owned 616,885 shares of CareDx common stock, held in direct ownership.

Was the CareDx CEO’s share sale made under a Rule 10b5-1 plan?

Yes. The filing states that the sale was executed under a Rule 10b5-1 trading plan adopted by the CEO on December 13, 2024.

What does the weighted average price disclosure mean in this CareDx Form 4?

The filing notes that $21.052 is a weighted average price for multiple trades between $21.00 and $21.18 per share, and that detailed trade prices are available upon request.

Does the Form 4 indicate indirect ownership or other entities for the CareDx CEO?

No. The reported holdings after the transaction are shown as direct ownership (D), with no nature of indirect beneficial ownership specified.

Caredx

NASDAQ:CDNA

CDNA Rankings

CDNA Latest News

CDNA Latest SEC Filings

CDNA Stock Data

1.04B
49.47M
3.43%
101.7%
12.97%
Diagnostics & Research
Services-medical Laboratories
Link
United States
BRISBANE